AT521353T - New trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-one derivative for treatment of CSBP / p38kinase mediated diseases - Google Patents

New trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-one derivative for treatment of CSBP / p38kinase mediated diseases

Info

Publication number
AT521353T
AT521353T AT01994463T AT01994463T AT521353T AT 521353 T AT521353 T AT 521353T AT 01994463 T AT01994463 T AT 01994463T AT 01994463 T AT01994463 T AT 01994463T AT 521353 T AT521353 T AT 521353T
Authority
AT
Austria
Prior art keywords
pyridoä2
trisubstitutiertes
p38kinase
düpyrimidin
csbp
Prior art date
Application number
AT01994463T
Other languages
German (de)
Inventor
Jerry Adams
Jeffrey Boehm
Ralph Hall
Qi Jin
Jiri Kasparec
Domingos Silva
John Taggart
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US24246100P priority Critical
Priority to US31034901P priority
Priority to US32661801P priority
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Priority to PCT/US2001/050493 priority patent/WO2002059083A2/en
Publication of AT521353T publication Critical patent/AT521353T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulfur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
AT01994463T 2000-10-23 2001-10-23 New trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-one derivative for treatment of CSBP / p38kinase mediated diseases AT521353T (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US24246100P true 2000-10-23 2000-10-23
US31034901P true 2001-08-06 2001-08-06
US32661801P true 2001-10-02 2001-10-02
PCT/US2001/050493 WO2002059083A2 (en) 2000-10-23 2001-10-23 Novel compounds

Publications (1)

Publication Number Publication Date
AT521353T true AT521353T (en) 2011-09-15

Family

ID=27399571

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01994463T AT521353T (en) 2000-10-23 2001-10-23 New trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-one derivative for treatment of CSBP / p38kinase mediated diseases

Country Status (22)

Country Link
US (8) US7323472B2 (en)
EP (2) EP1333833B1 (en)
JP (3) JP4524072B2 (en)
KR (1) KR100850812B1 (en)
CN (2) CN1847229B (en)
AT (1) AT521353T (en)
AU (1) AU2002246855B2 (en)
BR (1) BR0114829A (en)
CA (1) CA2426654C (en)
CY (1) CY1112100T1 (en)
CZ (1) CZ20031125A3 (en)
DK (1) DK1333833T3 (en)
ES (1) ES2372028T3 (en)
HK (1) HK1059562A1 (en)
HU (1) HU229471B1 (en)
IL (5) IL155367D0 (en)
MX (1) MXPA03003612A (en)
NO (1) NO326830B1 (en)
NZ (1) NZ524806A (en)
PL (1) PL362049A1 (en)
PT (1) PT1333833E (en)
WO (1) WO2002059083A2 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010563A1 (en) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AT521353T (en) * 2000-10-23 2011-09-15 Glaxosmithkline Llc New trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-one derivative for treatment of CSBP / p38kinase mediated diseases
JP2004521892A (en) * 2000-12-20 2004-07-22 メルク エンド カムパニー インコーポレーテッドMerck & Company Incoporated (Halo - benzo carbonyl) heterocyclic-fused phenyl-based p38 kinase inhibitors
AU2003207298B2 (en) 2002-02-12 2009-09-03 Glaxosmithkline Llc Nicotinamide derivates useful as p38 inhibitors
US7629350B2 (en) * 2002-04-19 2009-12-08 Smithkline Beecham Corporation Compounds
MXPA05007485A (en) 2003-01-14 2006-01-30 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia.
RU2328497C2 (en) 2003-05-05 2008-07-10 Ф.Хоффманн-Ля Рош Аг Condensed pirimidine derivative and pharmaceutics with crf related activity
CN1560035A (en) * 2004-03-12 2005-01-05 沈阳药科大学 5-hydroxylic indole-3-carboxylic ester kind derivantion
CA2590294A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US7842809B2 (en) * 2005-01-24 2010-11-30 Bayer Schering Pharma Ag Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
JP2008535822A (en) * 2005-03-25 2008-09-04 グラクソ グループ リミテッドGlaxo Group Limited Novel compounds
US7479558B2 (en) * 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
PE07412010A1 (en) * 2005-03-25 2010-11-25 Glaxo Group Ltd COMPOUNDS DERIVED FROM 3,4-dihydropyrimido [4,5-d] pyrimidin-2 (1H) -ONE AS p38 KINASE INHIBITORS
UY29440A1 (en) * 2005-03-25 2006-10-02 Glaxo Group Ltd new compounds
WO2006118914A2 (en) * 2005-04-29 2006-11-09 Children's Medical Center Corporation Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
US7723342B2 (en) * 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
WO2006133052A2 (en) * 2005-06-08 2006-12-14 Centocor, Inc. A cellular therapy for ocular degeneration
PE08232007A1 (en) * 2005-11-15 2007-08-09 Glaxo Group Ltd tosylate salt of 8- (2,6-difluorophenyl) -4- (4-fluoro-2-methylphenyl) -2 - {[2-hydroxy-1- (hydroxymethyl) ethyl] amino} pyrido [2,3-] pyrimidine -7 (8H) -one
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
EP2031965A4 (en) * 2006-06-16 2010-06-30 Glaxo Group Ltd Novel compounds
EP2034838A4 (en) * 2006-06-16 2012-01-04 Glaxo Group Ltd Novel compounds
EP2032142A4 (en) * 2006-06-16 2010-07-21 Glaxo Group Ltd Novel compounds
US8022205B2 (en) * 2006-08-08 2011-09-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivatives as PI3K inhibitor and use thereof
GB0621830D0 (en) * 2006-11-02 2006-12-13 Chroma Therapeutics Ltd Inhibitors of p38 mitogen-activated protein kinase
JO2985B1 (en) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co MAPK/ERK Kinase Inhibitors
EP2126045A4 (en) * 2007-01-30 2010-05-26 Univ Georgia Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc)
CA2691975C (en) 2007-07-01 2018-05-01 Lifescan, Inc. Single pluripotent stem cell culture
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
WO2009012428A2 (en) 2007-07-18 2009-01-22 Lifescan, Inc. Differentiation of human embryonic stem cells
CA2695225A1 (en) 2007-07-31 2009-02-05 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic endocrine
CN107574142A (en) 2007-11-27 2018-01-12 生命扫描有限公司 Differentiation of human embryonic stem cells
MX2010009251A (en) * 2008-02-21 2010-11-25 Centocor Ortho Biotech Inc Methods, surface modified plates and compositions for cell attachment, cultivation and detachment.
US8623648B2 (en) * 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
JP5734183B2 (en) 2008-06-30 2015-06-17 ヤンセン バイオテツク,インコーポレーテツド Differentiation of pluripotent stem cells
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
AU2009274517B2 (en) 2008-07-25 2015-03-26 The University Of Georgia Research Foundation, Inc. Compositions for Mesoderm derived ISL1+ Multipotent cells (IMPs), epicardial progenitor cells (EPCs) and multipotent CXCR4+CD56+ cells (C56Cs) and methods of use
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
EP2350265B1 (en) 2008-10-31 2019-04-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
AU2009308967C1 (en) 2008-10-31 2017-04-20 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
KR101687344B1 (en) * 2008-11-20 2016-12-16 얀센 바이오테크 인코포레이티드 Methods and compositions for cell attachment and cultivation on planar substrates
CA2744234C (en) 2008-11-20 2018-11-06 Centocor Ortho Biotech Inc. Pluripotent stem cell culture on micro-carriers
WO2010065275A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US20100260825A1 (en) * 2009-04-13 2010-10-14 Nair Madhavan G Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches
RU2540016C2 (en) 2009-07-20 2015-01-27 Янссен Байотек, Инк. Differentiating human embryonic stem cells
CA2768644A1 (en) * 2009-07-20 2011-01-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
AU2010276438B2 (en) 2009-07-20 2015-06-11 Janssen Biotech Inc. Differentiation of human embryonic stem cells
ES2665006T3 (en) 2009-10-29 2018-04-24 Janssen Biotech, Inc. pluripotent stem cells
SG181685A1 (en) * 2009-12-23 2012-07-30 Centocor Ortho Biotech Inc Differentiation of human embryonic stem cells
AU2010333839C1 (en) 2009-12-23 2016-07-21 Janssen Biotech Inc. Differentiation of human embryonic stem cells
SG183535A1 (en) 2010-03-01 2012-10-30 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
SG10201503652WA (en) 2010-05-12 2015-08-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
SG186749A1 (en) * 2010-07-09 2013-02-28 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
EP2611910B1 (en) 2010-08-31 2018-01-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CA2809305C (en) 2010-08-31 2019-06-11 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
WO2012030538A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2012054978A1 (en) * 2010-10-27 2012-05-03 Ludwig Institute For Cancer Research Limited Novel anti-cancer agents
WO2012073238A1 (en) 2010-12-02 2012-06-07 Technion Research & Development Foundation Ltd. Methods of generating corneal cells and cell populations comprising same
EP2652125B1 (en) 2010-12-15 2017-04-26 Kadimastem Ltd. Insulin producing cells derived from pluripotent stem cells
WO2012143510A1 (en) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
CN105143446A (en) 2011-12-22 2015-12-09 詹森生物科技公司 Differentiation of human embryonic stem cells into single hormonal insulin positive cells
DE102012200360A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted triazines and their use
DE102012200349A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted fused pyrimidines and triazines and their use
ES2644781T3 (en) 2012-03-06 2017-11-30 Bayer Intellectual Property Gmbh Azabiciclos substituted and use
WO2013134378A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
RU2018108847A3 (en) 2012-06-08 2019-02-26
US10138465B2 (en) 2012-12-31 2018-11-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
BR112015015770A2 (en) 2012-12-31 2017-07-11 Janssen Biotech Inc culturing human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
CN105308055B (en) 2013-03-01 2017-07-14 拜耳制药股份公司 Trifluoromethyl substituted fused pyrimidines and their use
AP201608970A0 (en) 2013-07-10 2016-01-31 Bayer Pharma AG Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
RU2694311C2 (en) 2014-05-16 2019-07-11 Янссен Байотек, Инк. Use of small molecules to increase expression of mafa in pancreatic endocrine cells
JP6394547B2 (en) * 2015-09-18 2018-09-26 トヨタ自動車株式会社 Vehicle control device
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2833779A (en) * 1956-10-29 1958-05-06 American Cyanamid Co Substituted pyrazoles
US3910913A (en) 1969-11-04 1975-10-07 American Home Prod 4,5-Diamino-7H-pyrrolo{8 2,3-d{9 pyrimidine derivatives
US3631045A (en) 1969-11-04 1971-12-28 American Home Prod 4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US3929807A (en) 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3725405A (en) * 1970-06-18 1973-04-03 American Home Prod 2,4,7-TRISUBSTITUTED-{8 PYRIDO 2,3-d{9 PYRIMIDINE-6-CARBOXAMIDES
US3795674A (en) * 1970-06-18 1974-03-05 American Home Prod Certain 2-substituted-4,6-diamino-5-pyrimidinecarboxaldehydes
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
CA966134A (en) * 1972-05-05 1975-04-15 Haydn W.R. Williams 1,8-naphthyridine compounds
US4058614A (en) 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
JPS634539B2 (en) * 1979-06-14 1988-01-29 Wellcome Found
GR75287B (en) * 1980-07-25 1984-07-13 Ciba Geigy Ag
GB2123831B (en) 1981-07-20 1986-01-15 Ciba Geigy Ag Trisubstituted oxazo compounds
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
JPH0559118B2 (en) 1984-04-24 1993-08-30 Nippon Zoki Pharmaceutical Co
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4560691A (en) * 1984-07-13 1985-12-24 Sterling Drug Inc. 5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467D0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
JPH01261306A (en) * 1988-04-13 1989-10-18 Nippon Kayaku Co Ltd Flowering promoter comprising 2-alkylthio-4-aminopyrimidine derivative as active ingredient
EP0470600B1 (en) 1990-08-10 1997-05-07 Novartis AG Naphthylalkylaminopyrimidine derivatives, process for their preparation and pesticides containing them
FR2665898B1 (en) 1990-08-20 1994-03-11 Sanofi Amide derivatives of 3-pyrazole, process for their preparation and pharmaceutical compositions containing them.
IE913473A1 (en) * 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
JPH06502178A (en) 1990-12-31 1994-03-10
JP3375659B2 (en) * 1991-03-28 2003-02-10 テキサス インスツルメンツ インコーポレイテツド Method of forming an electrostatic discharge protection circuit
CA2102780C (en) * 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
FR2676734B1 (en) 1991-05-23 1995-05-19 Roussel Uclaf New derivatives of pyrimidine, their method of preparing the new intermediaries obtained, their application as medicines and pharmaceutical compositions containing them.
IL102764D0 (en) 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
DE4131029A1 (en) 1991-09-18 1993-07-29 Basf Ag Substituted pyrido (2,3-d) pyrimidines as antidotes
US5716972A (en) * 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
AP9300477A0 (en) 1992-01-13 1993-01-31 Smithkline Beecham Corp Novel compounds
US6008235A (en) 1992-01-13 1999-12-28 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5916891A (en) * 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
US5466692A (en) * 1993-03-24 1995-11-14 American Home Products Corporation Substituted pyridopyrimidines and antihypertensives
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
EP0724588B1 (en) 1993-09-17 1999-11-10 Smithkline Beecham Corporation Drug binding protein
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
US5869043A (en) * 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
US5426110A (en) * 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
WO1995013067A1 (en) 1993-11-08 1995-05-18 Smithkline Beecham Corporation Oxazoles for treating cytokine mediated diseases
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5547954A (en) 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US5545669A (en) * 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US6268310B1 (en) 1997-01-28 2001-07-31 Nippon Soda Co., Ltd. Oxazole derivative, process for producing the same, and herbicide
EP0779292A4 (en) * 1994-08-29 1997-09-24 Yamanouchi Pharma Co Ltd Novel naphthyridine derivative and medicinal composition thereof
IL115256D0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
JPH08325248A (en) * 1995-05-26 1996-12-10 Chugoku Kayaku Kk New reagent for synthesizing tetrazole compound and production of tetrazole compound using the same
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
EA000622B1 (en) 1995-06-07 1999-12-29 Американ Хоум Продактс Корпорейшн A process for preparing biphenyl derivatives
US5760220A (en) * 1995-06-07 1998-06-02 American Home Products Corporation Process for preparation of biphenyl derivatives
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
ZA9700175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
CZ216498A3 (en) 1996-01-11 1999-08-11 Smithkline Beecham Corporation Novel substituted imidazole compounds
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US20020137696A1 (en) 1996-01-23 2002-09-26 Robert Tam Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en) 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
JP2000507224A (en) 1996-03-08 2000-06-13 スミスクライン・ビーチャム・コーポレイション Use as inhibitors of angiogenesis Csaid compound
WO1997033883A1 (en) 1996-03-13 1997-09-18 Smithkline Beecham Corporation Novel pyrimidine compounds useful in treating cytokine mediated diseases
JP2000507545A (en) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション The novel therapy for Cns damage
WO1997035856A1 (en) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
AU2521597A (en) 1996-04-12 1997-11-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyramidine derivatives
ZA9703884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6875769B2 (en) * 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
IL128188D0 (en) 1996-08-06 1999-11-30 Pfizer ,7-bicyclic derivatives substituted pyrido-or pyrimido-containing 6,6-or 6
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6455690B1 (en) 1996-10-16 2002-09-24 Robert Tam L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
SK48199A3 (en) * 1996-10-16 2000-01-18 Icn Pharmaceuticals Purine l-nucleosides, analogs and uses thereof
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
JP2000505109A (en) 1996-11-27 2000-04-25 ファイザー・インク Fused bicyclic pyrimidine derivatives
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
AT391719T (en) 1997-02-05 2008-04-15 Warner Lambert Co Pyrido (2,3-d) pyrimidine and 4-amino-primidine as inhibitors of cellular proliferation
US6362193B1 (en) * 1997-10-08 2002-03-26 Smithkline Beecham Corporation Cycloalkenyl substituted compounds
US6335340B1 (en) * 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
KR20010041015A (en) * 1998-02-17 2001-05-15 윌리엄 제이. 리플린 Anti-viral pyrimidine derivatives
US6306866B1 (en) 1998-03-06 2001-10-23 American Cyanamid Company Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents
JP2000038350A (en) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd Diabetes therapeutic drug
US6423425B1 (en) * 1998-05-26 2002-07-23 Ppg Industries Ohio, Inc. Article having a chip-resistant electrodeposited coating and a process for forming an electrodeposited coating
US20040044012A1 (en) * 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US6248225B1 (en) * 1998-05-26 2001-06-19 Ppg Industries Ohio, Inc. Process for forming a two-coat electrodeposited composite coating the composite coating and chip resistant electrodeposited coating composition
TR200003429T2 (en) 1998-05-26 2001-07-23 Warner-Lambert Company bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
EP1086085A1 (en) * 1998-06-12 2001-03-28 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
EP1114039A1 (en) * 1998-09-18 2001-07-11 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
AT232205T (en) * 1998-10-01 2003-02-15 Astrazeneca Ab Quinoline and quinazoline derivatives and which involved cytokine their use as inhibitors of diseases,
WO2000023444A1 (en) 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
TR200101102T2 (en) 1998-10-23 2002-01-21 F.Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
ES2260033T3 (en) * 1999-07-02 2006-11-01 Stuart A. Lipton Using p38 MAPK inhibitors in ophthalmic efermadades.
EP1223924A4 (en) 1999-09-17 2004-07-14 Smithkline Beecham Corp Use of csaids in rhinovirus infection
TR200201506T2 (en) 1999-09-17 2002-10-21 Abbott Gmbh & Co. Kg Kinase inhibitors as therapeutic agents
WO2001042243A2 (en) 1999-12-08 2001-06-14 Advanced Medicine, Inc. Protein kinase inhibitors
CA2673615C (en) * 2000-01-21 2013-07-16 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
IL150545D0 (en) 2000-01-25 2003-02-12 Warner Lambert Co PYRIDO [2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
IL150742D0 (en) * 2000-01-27 2003-02-12 Warner Lambert Co Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
AR030053A1 (en) * 2000-03-02 2003-08-13 Smithkline Beecham Corp 1H-pyrimido [4,5-d] pyrimidin-2-ones and salts, pharmaceutical compositions, use for the manufacture of a medicament and method for producing them
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
NZ520962A (en) 2000-03-06 2003-09-26 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines cyclin-dependent tyrosine kinase inhibitors
WO2002060869A2 (en) 2000-10-19 2002-08-08 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AT521353T (en) 2000-10-23 2011-09-15 Glaxosmithkline Llc New trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-one derivative for treatment of CSBP / p38kinase mediated diseases
JP2002205986A (en) * 2000-11-08 2002-07-23 Takeda Chem Ind Ltd Pyrimidine derivative and herbicide comprising the same
JP2004521892A (en) * 2000-12-20 2004-07-22 メルク エンド カムパニー インコーポレーテッドMerck & Company Incoporated (Halo - benzo carbonyl) heterocyclic-fused phenyl-based p38 kinase inhibitors
AU2002258400A1 (en) * 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
DE10108481A1 (en) * 2001-02-22 2002-10-24 Bayer Ag pyridylpyrimidines
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
CA2450934A1 (en) * 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
PE00082003A1 (en) * 2001-06-19 2003-01-22 Squibb Bristol Myers Co dual inhibitors of PDE 4 and PDE 7
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
JP4178783B2 (en) 2001-10-19 2008-11-12 三菱化学株式会社 An optical recording medium
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
BR0309581A (en) * 2002-05-06 2005-03-29 Genelabs Tech Inc nucleoside derivatives for the treatment of infection by hepatitis C virus
ITBO20020304A1 (en) * 2002-05-17 2003-11-17 Magneti Marelli Powertrain Spa New pipes made of polymeric material
TW200413381A (en) * 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7384937B2 (en) * 2002-11-06 2008-06-10 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
JP2004203751A (en) 2002-12-24 2004-07-22 Pfizer Inc Substituted 6,6-heterobicyclic derivative
EP1590341B1 (en) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US7138412B2 (en) * 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
MXPA05012839A (en) * 2003-05-27 2006-05-17 Pfizer Prod Inc Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors.
CA2554566A1 (en) * 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyramidine compounds as inhibitors of voltage-gated ion channels
DE102004020908A1 (en) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituted 5,6,7,8-tetrahydro-pyrido [4,3-d] pyrimidin-2-yl and 5,6,7,8-tetrahydro-quinazolin-2-yl compounds
US7098222B2 (en) * 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7479558B2 (en) 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
UY29440A1 (en) 2005-03-25 2006-10-02 Glaxo Group Ltd new compounds
PE07412010A1 (en) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPOUNDS DERIVED FROM 3,4-dihydropyrimido [4,5-d] pyrimidin-2 (1H) -ONE AS p38 KINASE INHIBITORS
JP2008535822A (en) 2005-03-25 2008-09-04 グラクソ グループ リミテッドGlaxo Group Limited Novel compounds
JP2008545696A (en) * 2005-05-23 2008-12-18 スミスクライン・ビーチャム・コーポレイションSmithkline Beecham Corporation Inhibition of p38mark for the treatment of obesity
WO2007036791A1 (en) 2005-09-28 2007-04-05 Ranbaxy Laboratories Limited Pyrido-pyridimidine derivatives useful as antiinflammatory agents
RS52953B (en) 2005-10-07 2014-02-28 Exelixis Inc. Pyridopyrimidinone inhibitors of pi3 kalpha
PE08232007A1 (en) 2005-11-15 2007-08-09 Glaxo Group Ltd tosylate salt of 8- (2,6-difluorophenyl) -4- (4-fluoro-2-methylphenyl) -2 - {[2-hydroxy-1- (hydroxymethyl) ethyl] amino} pyrido [2,3-] pyrimidine -7 (8H) -one
US20090170834A1 (en) * 2005-12-22 2009-07-02 Prolexys Pharmaceuticals, Inc. Fused Pyrimidones and Thiopyrimidones, and Uses Thereof
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
EP2086975B1 (en) * 2006-11-20 2012-03-14 Bristol-Myers Squibb Company 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods
JP5302389B2 (en) 2008-04-29 2013-10-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Pyrimidinyl pyridone inhibitors of Jnk

Also Published As

Publication number Publication date
IL192339D0 (en) 2008-12-29
US20050203109A1 (en) 2005-09-15
WO2002059083A2 (en) 2002-08-01
US20110009625A1 (en) 2011-01-13
IL192338D0 (en) 2008-12-29
HK1059562A1 (en) 2012-06-08
US8058282B2 (en) 2011-11-15
JP2010195795A (en) 2010-09-09
CN1847229A (en) 2006-10-18
EP1333833A2 (en) 2003-08-13
KR100850812B1 (en) 2008-08-06
NO326830B1 (en) 2009-02-23
IL155367A (en) 2010-12-30
IL192337D0 (en) 2008-12-29
US20110046109A1 (en) 2011-02-24
BR0114829A (en) 2003-09-23
US20080032969A1 (en) 2008-02-07
JP2009221233A (en) 2009-10-01
US20040209901A1 (en) 2004-10-21
JP4524072B2 (en) 2010-08-11
CY1112100T1 (en) 2015-11-04
EP1333833B1 (en) 2011-08-24
KR20040010548A (en) 2004-01-31
AU2002246855B2 (en) 2005-12-22
EP2404603A1 (en) 2012-01-11
US7323472B2 (en) 2008-01-29
PL362049A1 (en) 2004-10-18
HU0302274A3 (en) 2012-12-28
JP2004517922A (en) 2004-06-17
CN100525768C (en) 2009-08-12
CN1561216A (en) 2005-01-05
CN1847229B (en) 2011-05-04
MXPA03003612A (en) 2003-06-19
ES2372028T3 (en) 2012-01-13
NZ524806A (en) 2006-03-31
US7314881B2 (en) 2008-01-01
CZ20031125A3 (en) 2003-10-15
US20080033170A1 (en) 2008-02-07
DK1333833T3 (en) 2011-12-12
HU0302274A2 (en) 2003-11-28
PT1333833E (en) 2011-12-09
IL155367D0 (en) 2003-12-23
EP1333833A4 (en) 2007-10-24
US20090105478A1 (en) 2009-04-23
WO2002059083A3 (en) 2003-04-10
HU229471B1 (en) 2014-01-28
CA2426654A1 (en) 2002-08-01
US7759486B2 (en) 2010-07-20
NO20031794L (en) 2003-06-23
US20040116697A1 (en) 2004-06-17
NO20031794D0 (en) 2003-04-22
US7314934B2 (en) 2008-01-01
CA2426654C (en) 2010-12-21

Similar Documents

Publication Publication Date Title
DK1478358T3 (en) Sorafenibtosylat for the treatment of diseases characterized by abnormal angiogenesis
DE602004031390D1 (en) Coagulation factor VII-Fc chimeric proteins for the treatment of hemostatic disorders
AT521341T (en) Dna-damage-repair-inhibitors for treatment of cancer
DE602004007225D1 (en) Method for treatment of diseases of the lower urinary tract
DE60224189D1 (en) Dipeptidyl peptidase inhibitors for treatment of diabetes
DE60209348D1 (en) Dipeptidyl peptidase inhibitors for treatment of diabetes
DE60007001D1 (en) Neurotoxins for treatment of pancreatic diseases
DE60320007D1 (en) Phenethanolamine derivatives for treatment of airway diseases
DE60143801D1 (en) Treatment of obesity
DE60323090D1 (en) 1h-imidazoä4,5-cüchinolinderivate for treatment of protein kinase-dependent diseases
DE60138420D1 (en) System for treatment of tissue
AT478082T (en) Phosphonates monophosphonamidate, bisphosphonamidate for treatment of viral diseases
DE60138129D1 (en) Apparatus for treatment of teeth
DE60319066D1 (en) 1,4-disubstituted benzo-fused cycloalkyl urea compounds for the treatment of cytokine mediated diseases
DE60219292D1 (en) Pyrazole derivatives for treatment of hiv
AT282590T (en) Benzamide derivatives for treating cytokine mediated diseases
AT463247T (en) Bupropion metabolites for treatment of anxiety states
DE60225007D1 (en) Device for treatment of bowel dysfunctions
AT361117T (en) Device for treatment of heart failure
DE602004020072D1 (en) 1,2,3,4-tetra-substituted indole for treatment of airway diseases
DE60019556D1 (en) 2-amino-benzoxazinonderivate for treatment of obesity
AT375999T (en) Compositions and methods for treating diabetes
DE60136815D1 (en) Devices for treating wirbelkoerpern
AT401079T (en) The use of c-kithemmern for treatment of autoimmune diseases
DE60327800D1 (en) System for treatment of obesity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Country of ref document: EP

Ref document number: 1333833